Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart risk in hypoparathyroidism: could a Once-Daily injection protect arteries?

NCT ID NCT07707479

Disease control Sponsor: National and Kapodistrian University of Athens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study investigates whether long-acting parathyroid hormone (PTH) analogues can reduce signs of early heart and blood vessel damage in adults with chronic hypoparathyroidism. Researchers will compare artery stiffness and heart function in people taking the PTH analogue palopegteriparatide, those on standard therapy, and healthy volunteers. Participants will be followed for 12 months with vascular tests, heart imaging, and blood work to track changes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a long-acting parathyroid hormone (PTH) analogue called palopegteriparatide (TransCon PTH)
What this could lead to
If successful, this could show that PTH analogues protect the heart and arteries in people with hypoparathyroidism, potentially reducing their risk of cardiovascular disease.
What could go wrong
This is an observational follow-up study, not a randomized trial, so results may be influenced by other factors. The treatment is already approved, but its heart benefits are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 210 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults (≥18y) with chronic HypoPT (≥12 months) currently treated with conventional therapy or palopegteriparatide for more than one year and comparable healthy individuals, matched to patients based on key characteristics such as age, sex, and cardiovascular risk factors

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- Cross sectional arm: Baseline State: Adults (≥18y) with chronic HypoPT (≥12 months) currently treated with conventional therapy or palopegteriparatide for more than one year -Prospective Follow-up: Adults (≥18y) with chronic HypoPT (≥12 months) currently treated with conventional therapy and about to start treatment with palopegteriparatide willing to undergo baseline measurements (prior to the first dose) and repeat measurements at 3 and 12 months. Exclusion Criteria: * Renal Function: CKD Stage 3 or higher (eGFR \< 60 mL/min/1.73 m²) * Uncontrolled Risk Factors: * SBP \> 180/100 mmHg * Uncontrolled endocrine diseases (e.g., hyper- or hypothyroidism, diabetes mellitus type 2 with HbA1c\>7.5%). * Bone Health: Any metabolic bone disease other than hypoparathyroidism (excluding osteoporosis) * Documented Atrial Fibrillation (ECG) * Contraindication to long acting PTH analogue as per product labeling

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic hypoparathyroidism are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder hypoparathyroidism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic hypoparathyroidism

Contacts and locations

Locations

  • Alexandra General Hospital of Athens

    Athens, 11527, Greece

  • Medical School, National and Kapodistrian University of Athens, LAIKO General Hospital of Athens

    Athens, 11527, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.